Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals Top-Line Results of Second Cohort (50mg) of Part A of Phase 2 ACHIEVE Trial  (Replay)
    Thursday, November 16, 2017 8:00 am EST
Toggle Summary Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, at Keystone Symposia
HOPKINTON, Mass. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. , (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced two abstracts on SB 11285 , its
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results
HOPKINTON, Mass. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today provided an update on recent corporate and
Toggle Summary Spring Bank Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference in NYC on February 16
Untitled Document HOPKINTON, MA / ACCESSWIRE / February 7, 2017 / Spring Bank Pharmaceuticals Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll,
Toggle Summary Spring Bank Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference in NYC
HOPKINTON, Mass. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases today announced that Martin Driscoll , President
Toggle Summary Garrett Winslow Joins Spring Bank as Vice President of Legal
HOPKINTON, Mass. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer and inflammatory diseases, today announced that Garrett Winslow, Esq.
Toggle Summary Spring Bank and Arbutus Biopharma Announce Preclinical Collaboration in Study of Chronic Hepatitis B
HOPKINTON, Mass. , Dec. 19, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, and Arbutus Biopharma Corporation (NASDAQ:ABUS)
Toggle Summary Spring Bank Pharmaceuticals Announces Financing of $15 Million
Proceeds to Supplement Development of SB 9200 and SB 11285 HOPKINTON, Mass. , Nov. 18, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2016 Financial Results
Reaffirms on track to report initial results from the first dosing cohort in ACHIEVE Phase 2 chronic Hepatitis B trial of SB9200 during the first half of 2017 HOPKINTON, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical
Toggle Summary Spring Bank Pharmaceuticals Presents Data on STING Agonist SB 11285 at the AACR Special Conference on Tumor Immunology and Immunotherapy
Positive preclinical findings support advancement of SB 11285 into further development as a potential immunotherapeutic agent in cancer HOPKINTON, Mass. , Oct. 20, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel
Toggle Summary Spring Bank Pharmaceuticals to Present at Dawson James Securities 2016 Stock Growth Conference
HOPKINTON, Mass. , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll , President